Screening new tuberculosis patients in Mali for rifampicin resistance at 2months | Zendy

Bassirou Diarra | Zendy; Aissata Boubakar Cisse | Zendy; Ousmane Kodio | Zendy; M. Sanogo | Zendy; Bocar Baya | Zendy; Antieme Combo Georges Togo | Zendy; Anou M. Somboro | Zendy; Mohamed Tolofoudié | Zendy; Boureima Degoga | Zendy; Marie Laure Keita | Zendy; Fatimata Diallo | Zendy; Natacha Nguiakam | Zendy; Gagni Coulibaly | Zendy; Sidy Bane | Zendy; Yéya dit Sadio Sarro | Zendy; Seydou Doumbia | Zendy; Robert L. Murphy | Zendy; Souleymane Diallo | Zendy; Bouke C. de Jong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Screening new tuberculosis patients in Mali for rifampicin resistance at 2months

Author(s) -

Bassirou Diarra,

Aissata Boubakar Cisse,

Ousmane Kodio,

M. Sanogo,

Bocar Baya,

Antieme Combo Georges Togo,

Anou M. Somboro,

Mohamed Tolofoudié,

Boureima Degoga,

Marie Laure Keita,

Fatimata Diallo,

Natacha Nguiakam,

Gagni Coulibaly,

Sidy Bane,

Yéya dit Sadio Sarro,

Seydou Doumbia,

Robert L. Murphy,

Souleymane Diallo,

Bouke C. de Jong

Publication year - 2016

Publication title -

international journal of mycobacteriology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 20

eISSN - 2212-554X

pISSN - 2212-5531

DOI - 10.1016/j.ijmyco.2016.09.052

Subject(s) - genexpert mtb/rif , medicine , sputum , tuberculosis , rifampicin , drug resistance , prospective cohort study , mycobacterium tuberculosis , surgery , pathology , microbiology and biotechnology , biology

The recent call for universal drug susceptibility testing (DST) for all tuberculosis (TB) patients will be difficult to meet in settings where Xpert rollout is limited, such as low prevalence of HIV and Multi-drug Resistant Tuberculosis (MDR) settings. As recommended by World Health Organization (WHO) guidelines, the success of TB treatment is measured by Ziehl-Neelsen (ZN) microscopy or auramine-rhodamine fluorescent microscopy (FM) on sputum, in which conversion to negative smear at 2months (M) is an important predictor of treatment success, defined as a negative smear at 5M. The sputum smear that fails to convert to negative at 5M are screened for rifampicin resistance. We tested in a prospective study whether an early screen for rifampicin resistance, based on FM results at 2M, could detect MDR patients early, rather than screening all patients with GeneXpert MTB/Rif at baseline.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research